Skip to main navigation Skip to search Skip to main content

BI 1218-0091 DINAMO:A double-blind,randomised,placebo-controlled,parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 24 weeks, with a double-blind active treatment safety extension period to 52 we

Project: Research

Project Details

StatusActive
Effective start/end date01/6/19 → 01/6/27

Funding

  • Boehringer Ingelheim Pharmaceutical: $318,969.32